UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review

Lipids in health and disease, 2017-08, Vol.16 (1), p.149-149, Article 149

2017

Volltextzugriff (PDF)

ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model1

Journal of lipid research, 2020-03, Vol.61 (3), p.272-274

Hurt-Camejo, Eva

2020

Volltextzugriff (PDF)

An oral antisense oligonucleotide for PCSK9 inhibition

Science translational medicine, 2021-05, Vol.13 (593)

2021

Volltextzugriff (PDF)

Does statins promote vascular calcification in chronic kidney disease?

European journal of clinical investigation, 2017-02, Vol.47 (2), p.137-148

2017

Volltextzugriff (PDF)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]

Journal of lipid research, 2019-09, Vol.60 (9), p.1610-1621

2019

Volltextzugriff (PDF)

Lipids around the Clock: Focus on Circadian Rhythms and Lipid Metabolism

Biology, 2015-02, Vol.4 (1), p.104-132

2015

Volltextzugriff (PDF)

Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)

Journal of lipid research, 2021-01, Vol.62, p.100065, Article 100065

2021

Volltextzugriff (PDF)

ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker

Journal of cardiovascular development and disease, 2018-07, Vol.5 (3), p.36

2018

Volltextzugriff (PDF)

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease

Frontiers in pharmacology, 2022-09, Vol.13, p.988561-988561

2022

Volltextzugriff (PDF)

Abstract 13307: An Oral Antisense Oligonucleotide for PCSK9 Inhibition in Humans

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A13307-A13307

2020

Volltextzugriff (PDF)

Macrophages, extracellular matrix, and lipoproteins in arterial cholesterol balance

Journal of lipid research, 2014-01, Vol.55 (1), p.1-3

2014

Volltextzugriff (PDF)

Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis

Genome biology, 2007-09, Vol.8 (9), p.R200-R200, Article R200

2007

Volltextzugriff (PDF)

Endothelial Lipase Mediates HDL Levels in Normal and Hyperlipidemic Rabbits

Journal of Atherosclerosis and Thrombosis, 2012, Vol.19(3), pp.213-226

2012

Volltextzugriff (PDF)

Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease

ACS medicinal chemistry letters, 2016-10, Vol.7 (10), p.884-889

2016

Volltextzugriff (PDF)

Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers

Frontiers in pharmacology, 2021-08, Vol.12, p.681455-681455

2021

Volltextzugriff (PDF)

Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2 -IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease

Journal of the American College of Cardiology, 2014-03, Vol.63 (9), p.942-943

2014

Volltextzugriff (PDF)

ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model

Journal of lipid research, 2020-03, Vol.61 (3), p.272-274

Hurt-Camejo, Eva

2020

Volltextzugriff (PDF)

Stimulation of α7 nicotinic acetylcholine receptor by AR-R17779 suppresses atherosclerosis and aortic aneurysm formation in apolipoprotein E-deficient mice

Vascular pharmacology, 2014-05, Vol.61 (2), p.49-55

2014

Volltextzugriff (PDF)

High Plasma Phospholipase A 2 Activity, Inflammation Markers, and LDL Alterations in Obesity With or Without Type 2 Diabetes

Obesity (Silver Spring, Md.), 2012-09, Vol.18 (10), p.2023-2029

2012

Volltextzugriff (PDF)

Suppression of abdominal aortic aneurysm formation by AR-R17779, an agonist for the α7 nicotinic acetylcholine receptor

Atherosclerosis, 2016-01, Vol.244, p.113-120

2016

Volltextzugriff (PDF)

Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis

Molecular therapy. Methods & clinical development, 2018-09, Vol.10, p.17-28

2018

Volltextzugriff (PDF)

Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase

Journal of lipid research, 2010-07, Vol.51 (7), p.1801-1809

2010

Volltextzugriff (PDF)

Phospholipase A2 enzymes and the risk of atherosclerosis

European heart journal, 2012-12, Vol.33 (23), p.2899-2909

2012

Volltextzugriff (PDF)

Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis

Biochimica et biophysica acta. Molecular and cell biology of lipids, 2006-11, Vol.1761 (11), p.1301-1308

2006

Volltextzugriff (PDF)

Phospholipase A2 Modification of Low Density Lipoproteins Forms Small High Density Particles with Increased Affinity for Proteoglycans and Glycosaminoglycans

The Journal of biological chemistry, 1999-09, Vol.274 (36), p.25913-25920

1999

Volltextzugriff (PDF)

1 – 25 von 131

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(126)
Mit Volltextzugriff
(93)

Publikationsform

Sprache

Englisch
(130)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review

ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model1

An oral antisense oligonucleotide for PCSK9 inhibition

Does statins promote vascular calcification in chronic kidney disease?

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]

Lipids around the Clock: Focus on Circadian Rhythms and Lipid Metabolism

Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)

ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease

Abstract 13307: An Oral Antisense Oligonucleotide for PCSK9 Inhibition in Humans

Macrophages, extracellular matrix, and lipoproteins in arterial cholesterol balance

Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis

Endothelial Lipase Mediates HDL Levels in Normal and Hyperlipidemic Rabbits

Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease

Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers

Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2 -IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease

ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model

Stimulation of α7 nicotinic acetylcholine receptor by AR-R17779 suppresses atherosclerosis and aortic aneurysm formation in apolipoprotein E-deficient mice

High Plasma Phospholipase A 2 Activity, Inflammation Markers, and LDL Alterations in Obesity With or Without Type 2 Diabetes

Suppression of abdominal aortic aneurysm formation by AR-R17779, an agonist for the α7 nicotinic acetylcholine receptor

Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis

Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase

Phospholipase A2 enzymes and the risk of atherosclerosis

Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis

Phospholipase A2 Modification of Low Density Lipoproteins Forms Small High Density Particles with Increased Affinity for Proteoglycans and Glycosaminoglycans

Suchergebnisse filtern